Challenge

Great therapies demand great diagnostics and monitoring

Cancer Prevalance and Projections in U.S. Population from 1975 – 2040

An increasing number of patients are diagnose with cancer each year.

Number of clinical trials

The number of clinical trials are exponentially increasing, the immunotherapy market will receive a wide array of newly approved drugs.

This is also reflected in the current immunotherapy market size and forecast –projected from now until 2032.

Low Response Rate: Only 15–20% of patients benefit from immunotherapy -meaning 4 out of 5 may receive little to no effect.

Problem

Most patients endure ineffective treatment before getting the right one
Healthcare systems spend billions on therapies that don’t work
Delayed decisions lead to poorer outcomes and unnecessary suffering
Early identification of non-responders is key to better care and smarter spending

Solution

For Patients:
Faster access to effective treatments, fewer side effects, and improved outcomes
For Clinicians:
Confident, data-driven decisions that optimize care pathways early on
For Payers & Systems:
Reduced waste, better resource allocation, and measurable cost saving
T-cell imaging is the key to smarter immunotherapy - for patients, clinicians, and healthcare systems alike.

learn more